Clinical Trials Browser

Prostatic Neoplasms × relacorilant × 90 days × Clear all

NCT03674814 2026-03-31

Study of Drug 1 (Enzalutamide) Plus Drug 2 (Relacorilant) for Patients With Prostate Cancer

Phase 1 Completed

Prostatic Neoplasms